Clinical trials in Homburg – page 22

295 clinical trials in Homburg, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Homburg at a glance

295

clinical trials

Research sites2

Quick filters

295 trials in Homburg

Open in trial search

HER2 positive breast cancer

Not recruiting

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo

Study Comparing Trastuzumab Deruxtecan and Trastuzumab Emtansine for Patients with High-Risk HER2-Positive Breast Cancer with Residual Disease After Initial Treatment

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Trastuzumab Deruxtecan
Sponsor:Daiichi Sankyo Inc.

Contact Research Centre

Gastrooesophageal cancer

Not recruiting

Study on Regorafenib and Nivolumab for Patients with Advanced Gastro-Oesophageal Cancer

Registered drugNo placebo

Study on Regorafenib and Nivolumab for Patients with Advanced Gastro-Oesophageal Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Nivolumab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:University Of Cologne

Contact Research Centre

Atrial fibrillation+2

Not recruiting

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Bayer AG

Contact Research Centre

Malignant melanoma

Not recruiting

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug

Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Type 2 diabetes mellitus+2

Not recruiting

Study of LY3502970 for Adults with Obesity or Overweight and Type 2 Diabetes

Investigational

Study of LY3502970 for Adults with Obesity or Overweight and Type 2 Diabetes

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Orforglipron hemicalcium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Prostate cancer

Not recruiting

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug

Study of Apalutamide and Androgen Deprivation Therapy for Patients with High-Risk Prostate Cancer

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Apalutamide
Sponsor:Janssen Cilag International

Contact Research Centre

Crohn's disease

Not recruiting

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo

Study of RVT-3101 for Treating Moderate to Severe Crohn's Disease in Patients

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:RO7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Retinal artery occlusion

Not recruiting

Study on Alteplase for Vision Recovery in Patients with Acute Central Retinal Artery Occlusion

Registered drug

Study on Alteplase for Vision Recovery in Patients with Acute Central Retinal Artery Occlusion

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Universitaetsklinikum Tuebingen AöR

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Registered drug

Study of Pembrolizumab with Chemotherapy for High-Risk Early-Stage ER+/HER2- Breast Cancer Patients

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Doxorubicin
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Pulmonary arterial hypertension

Not recruiting

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:Seralutinib
Sponsor:GB002 Inc.

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Study on Regorafenib and Pembrolizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo

Study on Regorafenib and Pembrolizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Translational Research In Oncology

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Homburg

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on lymphoma and leukemia treatments, including studies evaluating novel therapies for chronic lymphocytic leukemia and various types of B-cell lymphomas.

Mantle Cell Lymphoma
Diffuse Large B-cell Lymphoma
Chronic Lymphocytic Leukemia

Multiple trials exploring CAR-T cell therapies and targeted treatment combinations.

02 Breast Cancer Research

Comprehensive studies investigating treatments for various types of breast cancer, particularly focusing on hormone receptor-positive and HER2-positive disease.

Early-Stage Breast Cancer
Triple-Negative Breast Cancer
HER2-Positive Disease

Evaluating new combination therapies and targeted treatments for improved patient outcomes.

03 Cardiovascular Medicine

Studies addressing heart failure prevention and treatment, with innovative approaches to reducing cardiovascular risks.

Heart Failure Prevention
Pulmonary Arterial Hypertension

Testing novel drug combinations to improve cardiovascular outcomes and patient quality of life.

Back to Germany All countries